| Title |
Medication use for the treatment of diabetes in obese individuals
|
|---|---|
| Published in |
Diabetologia, May 2017
|
| DOI | 10.1007/s00125-017-4288-1 |
| Pubmed ID | |
| Authors |
John P. H. Wilding |
| Abstract |
Obesity is a major cause of type 2 diabetes and may complicate type 1 diabetes. Weight loss for obese individuals with diabetes has many health benefits, often leads to improvement in glucose control and sometimes, in type 2 diabetes, near normalisation of abnormal glucose metabolism. Weight loss is difficult to maintain and attempts to lose weight may be undermined by some diabetes treatments such as sulfonylureas, thiazolidinediones and insulin. Whilst lifestyle support should be the primary approach to aid individuals who wish to lose weight, pharmacological approaches can also be considered. These include choosing glucose-lowering drugs or drug combinations that are weight neutral or result in weight loss or prescribing drugs that are specifically approved as anti-obesity medication. Given that some of the newer glucose-lowering medications that cause weight loss, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2i), are also being used or considered for use as anti-obesity drugs, it seems that the distinction between glucose-lowering medication and weight loss medication is becoming blurred. This review discusses the main pharmacological approaches that can be used to support weight loss in individuals with diabetes. |
X Demographics
The data shown below were collected from the profiles of 57 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 12 | 21% |
| Spain | 11 | 19% |
| United States | 4 | 7% |
| France | 3 | 5% |
| Japan | 1 | 2% |
| Germany | 1 | 2% |
| Mexico | 1 | 2% |
| Saudi Arabia | 1 | 2% |
| Canada | 1 | 2% |
| Other | 0 | 0% |
| Unknown | 22 | 39% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 41 | 72% |
| Practitioners (doctors, other healthcare professionals) | 12 | 21% |
| Scientists | 4 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 90 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 90 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 13 | 14% |
| Student > Bachelor | 11 | 12% |
| Student > Master | 8 | 9% |
| Researcher | 7 | 8% |
| Other | 5 | 6% |
| Other | 13 | 14% |
| Unknown | 33 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 32% |
| Biochemistry, Genetics and Molecular Biology | 6 | 7% |
| Agricultural and Biological Sciences | 6 | 7% |
| Nursing and Health Professions | 3 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Other | 6 | 7% |
| Unknown | 37 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 36. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 November 2022.
All research outputs
#1,146,915
of 25,732,188 outputs
Outputs from Diabetologia
#603
of 5,376 outputs
Outputs of similar age
#22,399
of 325,475 outputs
Outputs of similar age from Diabetologia
#10
of 65 outputs
Altmetric has tracked 25,732,188 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,376 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 24.7. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 325,475 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 65 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.